Q1 Earnings Forecast for LEXX Issued By HC Wainwright

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Lexaria Bioscience in a research note issued on Tuesday, July 1st. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.14) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Lexaria Bioscience’s Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.12) EPS and Q4 2026 earnings at ($0.11) EPS.

Lexaria Bioscience Stock Performance

NASDAQ LEXX opened at $0.90 on Wednesday. Lexaria Bioscience has a 52-week low of $0.82 and a 52-week high of $4.38. The company has a market capitalization of $15.72 million, a P/E ratio of -1.52 and a beta of 0.79. The company has a fifty day moving average of $1.02 and a 200-day moving average of $1.47.

Lexaria Bioscience (NASDAQ:LEXX) last posted its quarterly earnings data on Monday, April 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Lexaria Bioscience had a negative net margin of 1,784.03% and a negative return on equity of 111.84%. The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.14 million.

Institutional Trading of Lexaria Bioscience

A number of hedge funds have recently made changes to their positions in LEXX. HighTower Advisors LLC lifted its holdings in shares of Lexaria Bioscience by 61.4% during the 4th quarter. HighTower Advisors LLC now owns 21,023 shares of the company’s stock worth $44,000 after acquiring an additional 8,000 shares during the last quarter. Byrne Asset Management LLC raised its position in Lexaria Bioscience by 122.3% in the 1st quarter. Byrne Asset Management LLC now owns 28,905 shares of the company’s stock worth $49,000 after purchasing an additional 15,905 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in Lexaria Bioscience by 108.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,873 shares of the company’s stock worth $61,000 after purchasing an additional 15,050 shares during the period. Raymond James Financial Inc. purchased a new position in Lexaria Bioscience in the 4th quarter worth $127,000. Finally, Geode Capital Management LLC raised its position in Lexaria Bioscience by 10.8% in the 4th quarter. Geode Capital Management LLC now owns 166,679 shares of the company’s stock worth $350,000 after purchasing an additional 16,288 shares during the period. 13.06% of the stock is owned by institutional investors.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.